Nitric oxide (NO) is a molecule required for many physiological functions, produced from L-arginine by NO synthases (NOS). It is a free radical, producing many reactive intermediates that account for its bioactivity. Sustained induction of the inducible form of NOS (iNOS) in chronic inflammation may be mutagenic, through NO-mediated DNA damage or hindrance to DNA repair, and thus potentially ca...

BACKGROUND The recent decrease in myeloid leukemia incidence may be directly attributed to changes in the population-based cancer registries 2001 guidelines, which required the capture of only one malignancy in the myeloid lineage per person and the simultaneous adoption of myelodysplastic syndrome registration in the United States. METHODS We constructed four claims-based algorithms to asses...

Somatic mutations of DNMT3A gene have recently been reported in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We examined the entire coding sequences of DNMT3A gene by high-resolution melting analysis and sequencing in Chinese patients with myeloid malignancies. R882 mutations were found in 12/182 AML and in 4/51 MDS, but not in either 79 chronic myeloid leukemia (CML), or 57...

A murine monoclonal antibody (WI-5) was produced against a myeloid leukemia cell line (KG-1). The antibody was immunoglobulin G3K. It reacted only against KG-1 cells and failed to react against 33 other cell lines representing fibroblasts, solid tumors, and cells of myeloid and lymphatic origin. It also showed no reaction against normal red blood cells, granulocytes, platelets, monocytes, and T...

background the induction ofâ  cancers incidence by exogenous agents, such as chemical, radiation and especially research on viruses is an interestedâ  area of active basic subjectsâ  and clinical investigation. prominent researches sounds aâ  high prevalence of hbv marker has been found in patients with leukemia as compared to the general population. methods: presentâ  â study was conducted fro...

background and objectives: bone marrow necrosis (bmn) is a rare and ominous complication of wide variety of diseases including hematologic malignancy. this study was performed to identify frequency and the underlying associated diseases of marrow necrosis. materials and methods: in this descriptive study, totally 850 bone marrow trephine biopsies related to living patients at the pathology depa...

  Background and Objectives: Bone marrow necrosis (BMN) is a rare and ominous complication of wide variety of diseases including hematologic malignancy. This study was performed to identify frequency and the underlying associated diseases of marrow necrosis. Materials and Methods: In this descriptive study, totally 850 bone marrow trephine biopsies related to living patients at the Pathology ...

OBJECTIVE To determine the frequency of mutations in exon 11 of the c-kit gene in patients with leukemia. MATERIAL AND METHODS The study included 50 leukemia patients (31 with acute myeloid leukemia, 5 with acutelymphoblastic leukemia, 9 with chronic myeloid leukemia, and 5 with chronic lymphocytic leukemia) that underwentPCR-SSCP, followed by direct DNA sequencing. RESULTS In all, 28 of th...

Imatinib mesylate is the first tyrosine kinase inhibitor developed and approved for the treatment of chronic myeloid leukemia (CML). In the past few years development of resistance towards imatinib mesylate has been reported. To overcome this problem a series of phenyl amino pyrimidine derivatives have been designed, prepared and evaluated for ant...

JEM © The Rockefeller University Press $15.00 Vol. 204, No. 3, March 19, 2007 461–465 www.jem.org/cgi/doi/10.1084/jem.20062335 461 Chronic myeloid leukemia (CML), which is caused by the BCR–ABL fusion tyrosine kinase, is one of the most intensively studied human cancers. ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistanc...